3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Advanced Cancer
4
Stomach Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Neoplasms
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
23
Capecitabine
17
Cisplatin
11
Oxaliplatin
10
Fluorouracil
9
Leucovorin
8
Irinotecan
7
Erlotinib Hydrochloride
6
pembrolizumab
5
Radiotherapy
5
Sorafenib
4
Interleukin-12 Subunit p35
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
regorafenib
2
dehydroftorafur
2
Watchful Waiting
2
Trastuzumab
2
Pancreaticoduodenectomy
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Long-Term Synaptic Depression
2
Lapatinib
2
Filgrastim
2
Epirubicin
2
Drug Therapy
2
Dihematoporphyrin Ether
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bile Duct Neoplasms
×
ARRY-334543
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts